INTRODUCTION AND OBJECTIVES:
The AUA Quality (AQUA) Registry now includes data on >4.3M patients managed by over 1500 urologists across the country. AQUAs databases are populated by automated extraction of data from a variety of EHR systems. Some data (e.g., billing codes and orders) usually exist as structured data in EHRs. Others (e.g., cancer grade) usually do not, and must be identified via regular expression or the use of natural language processing. As a test of data extraction quality, we performed a patientlevel validation of prostate cancer data from two AQUA practices compared to the manually abstracted data available through their participation in the Michigan Urological Surgical Improvement Collaborative (MUSIC).
METHODS: Data were collected from men newly diagnosed with prostate cancer between 2014 and 2017 at two urology practices in Michigan. AQUA data were extracted using EHR connector software (FIGMD Inc, San Diego, CA), and MUSIC data were manually abstracted by trained staff at each site with annual onsite quality audits. Date of diagnosis, Gleason score (primary and secondary), diagnostic PSA, number of biopsy cores (positive and total), clinical staging, and primary treatment were compared. Percent of cases with missing information on each variable was also evaluated for both registries.
RESULTS: A total of 725 patients from the two practices were linked between AQUA and MUSIC registry. The rate of missing data in each registry as well as matching rates for values when identified are shown in Table 1 . The most common mismatches for treatment were between brachytherapy and external-beam radiation, and between radiation and primary androgen deprivation.
CONCLUSIONS: Automated extraction of both structured and unstructured data from EHRs is possible, and has the potential to substantially reduce the time and cost of disease registry population. Adjustments to algorithms will continually improve the quality of the automated abstraction. (14, 080) . Furthermore previous studies have shown that a large percentage of patients do not use or fill the prescription for their analgesics. In this study, we evaluated whether ketorolac was equally as effective at pain control as oxycodone after routine outpatient urologic procedures. Secondarily, we evaluated whether patients disposed the leftover medications appropriately. We hypothesize that toradol is noninferior to oxycodone, and that majority of patients do not dispose of their medications appropriately.
METHODS: Patients undergoing routine outpatient urologic procedures with a GFR >40 ml/min/1.73 m2, were consented to participate in the study. Patients were randomized into the oxycodone (5mg tablet, 1-2 tablets every 4 hours for 5 days) or the ketorolac (10mg tablet, 1 tablet every 6 hours for to 5 days) arm. Patient demographics, Charlson Comorbidity score, operative procedure details, and complications were recorded. A phone survey was conducted one week after surgery to determine level of pain control, number of pills taken, and method of pill disposal. A validated pain scale (Indiana Polyclinic Combined Pain Scale) was used to elicit patient responses about their post-operative pain.
RESULTS: A total of ninety-one patients were recruited. Table 1 shows that overall there was no difference in demographics between the two groups. The oxycodone group used significantly more pills compared to ketorolac (7.4 vs 3.1; p [ 0.005). In addition, the oxycodone group was significantly more likely to hold onto their pills or dispose them inappropriately despite being provided written and oral instruction on appropriate disposal methods. There was no difference in pain levels.
CONCLUSIONS: Toradol is a non-inferior alternative to oxycodone for outpatient urologic procedures in properly selected patients. A large percentage of patients in both groups did not fill or use their analgesics. Only 9% of patients disposed of their medications appropriately. Patient and physician education is necessary to curtail the indiscriminate prescription, use, and disposal of opioids.
